ULT Timing — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

EasyCrystal ArthropathyULT TimingSCE Rheumatology

An adult has experienced a clinically diagnosed gout flare but has none of the features for which NICE recommends directly offering urate-lowering therapy (ULT). According to current NICE guidance, when should the option of treat-to-target ULT be discussed?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — After a first or any subsequent gout flare

NICE recommends discussing the option of treat-to-target ULT after a first or any subsequent gout flare, even when the patient does not have a mandatory indication for treatment. By contrast, ULT should be offered to people with multiple or troublesome flares, CKD stages 3–5, diuretic therapy, tophi or chronic gouty arthritis. Therefore, treatment discussion is not deferred until a second or third flare, a serum urate threshold of 600 micromol/L, or the development of tophi. The timing of this discussion is distinct from treatment initiation: ULT is generally started at least 2–4 weeks after a flare has settled, although it may be started during a flare when flares are frequent.

Reference: National Institute for Health and Care Excellence. Gout: diagnosis and management (NG219), section 1.5, recommendations 1.5.1–1.5.4. 2022. https://www.nice.org.uk/guidance/ng219/chapter/Recommendations